Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss key data updates and trends in chronic myeloid leukemia after ASH 2024.

EP. 1: Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

EP. 2: Factors That Influence Treatment Decisions in Later-Line CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

EP. 3: 5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

EP. 4: Emerging Mutation Analysis from the OPTIC Trial

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

EP. 5: Dosing Strategies for Ponatinib in CML and ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

EP. 6: The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

EP. 7: Selecting a TKI in Subsequent Lines of Therapy in CML

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

EP. 8: Highlighting Key CML/ALL Data Presented at ASH 2024

January 23rd 2025

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.